3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
Aurinia Pharmaceuticals (NASDAQ: AUPH) stock is without question one of the best-performing biotech stocks so far in 2017. Shares of the red-hot biotech have tripled in price year to date. Aurinia reported great results from a phase 2 study of experimental lupus nephritis drug voclosporin in March, causing the stock to skyrocket.
The big question for investors now, though, is: Can Aurinia Pharmaceuticals stock go even higher? Here are three charts that show the answer to that question is "yes" -- at least over the long term.
Image source: Getty Images.
Source: Fool.com
Aurinia Pharmaceuticals Inc. Aktie
6,57 €
10,67 %
Die Aurinia Pharmaceuticals Inc. Aktie hat zu wenige Einschätzungen, um eine klare Tendenz abzulesen.
Ein unerwartetes Potenzial von 52.11% für Aurinia Pharmaceuticals Inc., obwohl das Kursziel von 10 € den aktuellen Kurs von 6.57 € übertrifft.
